P/E của cổ phiếu CGEN là bao nhiêu?

COMPUGEN (CGEN) hiện giao dịch ở mức P/E 3.89 lần.

ROE của cổ phiếu CGEN là bao nhiêu?

COMPUGEN có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 36.55%.

Tỷ suất cổ tức của CGEN là bao nhiêu?

COMPUGEN có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của CGEN là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của CGEN ở mức 62/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu CGEN không?

Điểm AI Timing của CGEN là 94/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu CGEN thuộc ngành nào?

COMPUGEN được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu CGEN (NASDAQ) | COMPUGEN

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CGEN AI Analysis Summary

Our AI summary for CGEN: COMPUGEN (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.89, ROE of 36.55%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 94/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CGEN

COMPUGEN

US:NASDAQ STOCK Healthcare >> Biotechnology News 86

USD 2.35

0.02 (0.64%) Day Change

Watchlist Portfolio Compare Chart

3.89

P/E

0.01

D/E

36.6%

ROE

23.9%

ROA

0.00%

Div Yield

-0.03

PEG

COMPUGEN
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.35 Price 0.02 (0.64%) Day Change	NEWS SCORE: 86

CGEN Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 62) và Thời điểm mua ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: [-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

58%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	86
Magic Formula Rank by ROA	63 GOOD
Magic Formula Rank by ROE	63 GOOD
Magic Formula Rank by ROIC	52 GOOD
Price	2.35
PBV / Sector	2.32 / 5.20
Earning Per Share	0.37

PE / Sector	3.89 / 19.97 GREAT
PEG or PE/Growth / Sector	-0.03 / 1.22
Average 1M Daily Value	0.56 M GREAT
Average 1W Daily Value	0.46 M GREAT

Yếu tố Kỹ thuật

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	47.97 / 98.71 GREAT
NPM Average (%) / Sector	-91.97 / -1,721.76
NPM Change Average (%) / Sector	-73.19 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	23.90 / 27.02 GOOD
ROA Average (%) / Sector	-3.44 / -368.17
ROA Change Average (%) / Sector	-88.18 / 5,404.12
ROE (%) / Sector	36.55 / 3.47 GREAT
ROE Average (%) / Sector	-5.39 / 6.51
ROE Change Average (%) / Sector	-67.49 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Chi tiết đăng ký

Analyze Date	2026-08-01 07:59:38
Symbol	CGEN
Name	COMPUGEN
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	94.58 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	220.86 / 9,903.94

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Azrieli Center, Holon, Israel, 5885849

Phone: 972 3 765 8585

Website: https://cgen.com

Employees: 75

Sector: Healthcare >> Biotechnology

Description: Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.